Pediatric Off-Patent Study Requests Will Not Mirror Rate For Exclusivity

FDA does not expect to issue written requests for studies of off-patent drugs at the same rate it has for patented drugs seeking pediatric exclusivity, Office of Counterterrorism & Pediatric Drug Development Director Dianne Murphy, MD, said